Investigators say that a biomarker in the blood--carbohydrate antigen 125, or CA125--offers a shot at a relatively low-cost approach to identifying ovarian cancer at an early stage, while the chances of survival are much higher.
In a recent study, researchers at Yale School of Medicine have identified a key link between stem cell factors that fuel ovarian cancer's growth and patient prognosis.
BRCA1 and BRCA2 mutations are already used as biomarkers to point out those people at increased risk of breast and ovarian cancer, but they could also pinpoint the women most likely to respond to Abbott's investigational cancer drug, veliparib.
KRAS is a known cancer-causing gene, linked with lung, pancreatic and colorectal cancer, as well as leukemia. A study published in PLoS One has also linked a variant of the gene with ovarian and breast cancer, finding it in almost half of women with both cancers. It could have potential as a biomarker.
Researchers from the Dana-Farber Cancer Institute have created a score based on the expression of genes involved in the repair of DNA after platinum-based treatment to see if this could predict the response, but the take on this is mixed.
As the fifth leading cause of cancer-related death in women in the U.S., ovarian cancer is a tough diagnosis to deal with, especially if the cancer comes back. Biomarkers can be used to point to the
Ovarian cancer is a silent killer--most women present late, and only have a 30% survival rate over 5 years. However, if it is diagnosed early, 90% of these women could survive, and a panel of
Ovarian cancer can be hard to treat--because the disease can have non-specific symptoms, patients often only come forward when the cancer is quite advanced. Additionally, some women develop
A new genetic screening method called BROCA located mutations in 12 genes for inherited cancers of the ovary, fallopian tubes and peritoneum. The study, led by Dr. Elizabeth Swisher at the University
The FDA has given 510(k) clearance to Fujirebio Diagnostics to market the company's test to detect whether the silent killer of ovarian cancer is stalking women who come into physicians' offices with